Pfizer Canada To Be Truly Healthy, It Takes More Than Medication

Innovation Gap

!  “We intend to make our internal capability even more effective by tapping into the best scientific capability outside of our walls -wherever it exists. That’s why we are reaching out to scientists around the world.” Jeff Kindler, CEO, Pfizer

Innovation Gap

Understanding Disease Biology is not a Competitive Activity

Canadian Public-Private Partnership Models of Innovation

Collaborative R&D Partnerships Centers of Excellence in Commercialization (CECRs) Quebec Pain Research Network (QPRN) Ontario Institute of Cancer Research (OICR) Center for Drug Research & Discovery (CDRD)

Pre-Competitive R&D Partnerships Quebec Drug Discovery Consortium (CQDM) Structural Genomics Consortium (SGC)

Partnership Models of Innovation Pre-Competitive Competitive

IRMA : THE DRUG REPOSITIONING

INITIATIVE

World class science drives the day…… Very significant internal competition for global R&D $$s

Local affiliates can drive internal global recognition of local opportunities, through local resources and local funds.

Alignment with large consortia and public funding is very helpful

In the Future Public-Private and Pre-competitive research is growing ON is in position to excel in this emerging paradigm

Public support of PPP is not a temporary concept. Funding must be maintained, as a basis for attracting other $$s into the project.

Canadian Public-Private Partnership Models of Innovation

Slide 1

Enable Integrate Engage

A New Model for the Translation of Regenerative Medicine: Collaborative, Capital-Efficient Technology Development

New Models of Innovation in Life Sciences

April 20th, 2011, MaRS, Toronto

Michael H. May PhD CEO

Slide 2

“Open Innovation” is Not New

Non-Zero-Sum Gain

“NONZERO – The Logic of Human Destiny”, Robert Wright

Collaboration

Technology

Environmental Stress or Need

Open Innovation

Zero-Sum Gain

Competition

Slide 3

Funding of Research and Commercialization in Canada

Slide 4

CCRM Builds on MaRS and MI

!"#$%&'()'*%&#+!#,-..-*%#/%%)/..0#*%#123#

Slide 5

A Global Nexus for RM Technology and Commercialization

Mission: To bridge the RM commercialization gap by leveraging funding and infrastructure,

and mobilizing business and scientific expertise to translate technologies

Product Development Basic R&D

Pre-Commercial Validation

Clinical & Commercial Validation

Existing Government

Programs

Industry Investment

Capital

Slide 6

Enable Product Development

Integrate Science and Business

Create Links to Market

Our Plan to Bridge the RM Commercialization Gap

Existing Government

Programs

Industry Investment

Capital

Slide 7

Translation through Collaboration

Slide 8

  capital efficient RM development

  utilize academic infrastructure   facilitate global collaboration

  focus on key bottlenecks   explore alternative funding sources

Slide 9

Slide 10

Industry Engagement Platform 1 Platform 2 Platform 3 4 companies, 2

Canadian, 2 large and 3 small

6 companies, 2 Canadian, 3 large

and 3 small

6 companies, 2 Canadian, 1 large

and 5 small

Foundational Reagents, tools and processes

Community Offerings Market Needs

! Cell culture bioprocesses, sensors and scale-up / out

Clinical and commercial quantities of stem/differentiated

cells

!  iPSC cells !  Lineage reprogramming ! Stem cell characterization

and standardization

Characterized and validated stem cell lines

! Biomaterials/biocompatibility !  Therapeutic polymers ! Microfabrication !  Functional and stabilized,

cell-derived tissues

Tissue mimetics for drug screening & transplantation

Slide 11

Driving Open Innovation

Non-Zero-Sum Gain

Zero-Sum Gain

Collaboration

Technology

Environmental Stress or Need

" Capital efficient " Pre-competitive

evidence-based infection control

!"

Evidence-based Infection Control!#$%"&'(')*+",-./0')$%"1%'0-*"'*2-34)*"3)*5%)6"$('*7"7-)(8/4/6"/*/6943(:"5)";)*'5)%:";-/($%-:"/*1"';8%)0-")$53);-(<"

#$%"=)/6+">-68"/3.'-0-"/*1"-?3--1"8/4-*5"(/2-59"';8-%/40-("@"8%')%'4-("

A"B-/%("C$;$6/40-"D-/%*'*7+"E'(-/(-"($%0-'66/*3-"/*1"'*2-34)*"3)*5%)6"()6$4)*(<"

F "G)()3);'/6"3/(-";/*/7-;-*5"F "H$5);/5-1"./*1".97'-*-"3);86'/*3-";)*'5)%'*7"F "H$5);/5-1")$5I%-/J"3)*5/35"5%/3'*7""F "K>)5L(8)5M"'1-*4N3/4)*"F "O-/6L4;-"@"($(5/'*-1"5%/3J'*7:"/6-%5("@";-5%'3("

!"

3

Incremental innovation tends to be ‘evolutionary’. Small improvements in existing practices.!

Disruptive innovation improves a product or service in ways that the market does not expect and looks to make significant impacts.!

Goal in healthcare is affordability/sustainability while increasing accessibility, quality and safety. This sector should be an ideal target for disruptive solutions.!

Innovation in Healthcare...!

P"

Open Innovation!

• C)*0-%7-*3-"Q)6$4)*"• R/%5*-%("S'5."H6'7*-1"=)/6("• C)*N%;"&'(')*"/*1"R/5."

• T/'*5/'*"5.-"&'()*"

• =-5M-%"E)*-"

!"#$%&"'()*+",-"./&-"0--,1$2,-"

34&"'5#"

'5#6",/&-"$77&%%"%70&-7&"•  8,9:&*"0-";<<="(,">&-&9$(&"?-,@A&*>&"$B,)("4):$-"/9,(&0-%"

•  C&%)A(%"$-*"9&$>&-(%"0-(,"/)BA07"*,:$0-"@0(4,)("9&%(9072,-"

•  D,"-,("EA&"F,9"GH",-"$-+"9&%)A(%"

•  =<I",F">A,B$A",)(/)(",F"-&@"4):$-"$-*"/$9$%0(&"/9,(&0-"%(9)7()9&%"

•  ;"/$/&9%"/&9"@&&?"

!"/)BA07J/901$(&"/$9(-&9%40/"

H4$9:$"

K&AA7,:&"39)%("

#$-$*$"

'@&*&-"

.-($90,"

Industrial focus yields HQP

Former SGC members:

•  > 65 scientists went on to jobs in academia •  15 to leadership positions (7 Faculty positions)

•  > 33 to industry (9 to leadership positions) •  7 returned to the SGC/or relocated to another SGC site •  4 to business schools

Training at SGC:

•  187 external scientists trained at the SGC (20 coop students)

No IP facilitates collaboration •  More than 200 Collaborations in 17 countries world wide •  ~250 publications – an average of 3.1 non-SGC scientists per paper

1 collaboration

2-5 collaborations

5-10 collaborations

10-20 collaborations

> 20 collaborations

>1000 expression clones have been sent out during the past 3 years of which more than 800 to academia

Knowledge transfer •  Over the last 3 years SGC scientists attended >250 conferences the majority of them as speakers

•  Serve on SAB’s of 5 biotech companies; 3 research consortia and 2 funding agencies •  The SGC organised 20 workshops/conferences during the past three years

•  More than 50 face-to-face meetings with industry per year

•  More than 100 external scientists attended workshops held at SGC

Technology development

Testing and Improvement of a number of different products/machines in collaboration with vendors: Crystallisation:

!  JCSG+ crystallization screen !  Mosquito crystallization robot !  Minstrel imaging robot !  Actor anti-icing lid !  SpearLab Liquid nitrogen handling dewars Compound screening !  Stratagene/Agilent RT-PCR !  Stargazer !  BMG Labtech multi-functional plate reader "Polarstar Omega“ !  Biacore with GE Healthcare Other !  Contur ELN

SGC driven developments: !  Lex System !  BeeHive (w. MolSoft, Inovacia, CPR) !  iSee (MolSoft) !  Software for domain boundary analysis !  Expression clone generating platform !  Phage-resistant bacterial host strains !  Proximity assay !

Commercialization

Harbinger Biotech, founded in 2005, has sold equipment to over 30 labs in industry and academia in Asia, North America and Europe

SGC software programs distributed to >40 labs

1DegreeBio founded in 2010

G-*)%(9+"H)BA07"D,:$0-"

H)BA07LH901$(&"H$9(-&9%40/"

Chemical Probes

Screening Chemistry Structure Bioavailability

Target Validation

No IP No restrictions Publication

Drug Discovery

(re)Screening Chemistry Lead optimization Pharmacology DMPK Toxicology Chemical development Clinical development

Moving the Pre-Competitive Boundary

Creative commons Proprietary

Impact of novel BET probe

250+ labs across the globe

Identified Jan 10

Published Sep 10

Distributed Jan 11